Dupilumab as a novel steroid-sparing treatment for IgG4-related disease
- 1 April 2020
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 79 (4), 549-550
- https://doi.org/10.1136/annrheumdis-2019-216368
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre studyScientific Reports, 2018
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Commonality of the IL-4/IL-13 pathway in atopic diseasesExpert Review of Clinical Immunology, 2017
- IgG4-related diseaseThe Lancet, 2015
- Rituximab and Immune Deficiency: Case Series and Review of the LiteratureThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011Modern Rheumatology, 2012